ANTITUMOR ACTIVITY OF SOME DERIVATIVES OF INDOLO[2,3-A]CARBAZOLES N-GLYCOSIDES WITH XYLOSE CARBOHYDRATE RESIDUE

Introduction. The search for new antineoplastic agents in a series of indolo[2,3-a]-carbazole derivatives is an urgent and promising direction, since compounds with antitumor activity have been found in this class. In the chemical fusion laboratory, N.N. Blokhin National Medical Research Center оf the Ministry of Health of Russia has developed an original and effective method for the synthesis of glycosides of indolo[2,3-a]-pyrrolo[3,4-c]carbazoles, which makes it possible to synthesize derivatives of N-glycosides of indolo[2,3-a]carbazoles with different substituents in the heterocyclic parts including at the maleimide nitrogen atom and with different carbohydrate residues.

The purpose of the study – the primary assessment of the antitumor activity of new derivatives of indolocarbazoles with a carbohydrate residue xylose in models of tumor growth mice.

Materials and methods. The compounds studied at transplanted tumors of mice: the Lewis epidermoid carcinoma (LLC), colon cancer ACATOL, cervical cancer RSHM-5, breast adenocarcinoma CA-755. Studies were performed on immunocompetent mice: males and females of BDF1 hybrids (C₅₇Bl/₆ × DBA/2), females CBA/Lac and Balb/c. Compound solutions were prepared ex tempore and administered to the mice intraperitoneally at a dose of 60 mg/kg daily for five days. The antitumor effect was evaluated as to of tumor growth inhibition and increase of life span of the treated animals as compared with the control ones.

Results. Eight compounds studied, containing D-xylose as a carbohydrate component and various substituents at the maleimide nitrogen atom, showed different degrees of antitumor activity. Two derivatives have been identified: N-[5,7-dioxo-12-(β-D-xylopyranosyl)-indole[2,3-a]pyrrolo[3,4-c]carbazol-6-il]benzamide (compound 4) and N-[5,7-dioxo-12-(β-D-xylopyranosyl)-5,7,12,13-tetrahydro-6H-indole[2,3-a]pyrrolo[3,4-c]carbazole-6-il]pyridin-2-carboxamide (compound 8), which showed high antitumor activity on 4 solid tumors of mice with a duration of effect of 12 days or more. The most pronounced antitumor effect was obtained in compounds 4 and 8 in RSHM-5 and Ca-755, tumor growth inhibition was amounted, respectively: in RSHM-5 – 68–82 % and 80–72 %; for Ca-755 – 57–62 % and 86–68 % (p <0.05).

Conclusion. For further research, we chose the compound (N-[5,7-dioxo-12-(β-D-xilopiranosil)-5,7,12,13-tetrahydro-6H-indole[2,3-a] pyrrolo[3,4-c]carbazol-6-il]pyridin-2-carboxamide).

1. Sánchez C., Méndez C., Salas J.A. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep 2006;23:1007–45. DOI: 10.1039/b601930g.

2. Bashir M., Bano A., Ijaz A.S., Chaudhary B.A. Recent developments and biological activities of n-substituted carbazole derivatives: A review. Molecules 2015;20(8):13496–517. DOI: 10.3390/molecules200813496.

3. Kiseleva M.P., Pokrovsky V.S., Tatarskiy V.V. et al. Indolocarbazile derivatives – a promising class of anticancer drugs. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(4):20–26. (In Russ.).

4. Saif M.W., Diasio R.B. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer 2005;5(1):27–36. DOI: 10.3816/ccc.2005.n.014. PMID: 15929804.

5. Yamada Y., Tamura T., Yamamoto N. et al. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemotherapy and Pharmacology 2006;58(2):173–82. DOI: 10.1007/s00280-005-0149-6.

6. Nock C.J., Brell J.M., Bokar J.A. et al. A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs 2011;29(1):126–30. DOI: 10.1007/s10637-009-9322-9.

7. Golubeva I.S., Yavorskaya N.P., Ektova L.V. et al. Comparison of the antitumor activity of indolocarbazole derivatives with carbohydrate residues galactose, arabinose and substituents on the imide nitrogen atom. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2017;16(S1):23. (In Russ.).

8. Prudhomme M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Current Medicinal Chemistry – Anti-Cancer Agents 2004;4(6):509–21. DOI: 10.2174/1568011043352650.

9. Civenni G., Longoni N., Costales P. et al. EC-70124, a novel glycosylated indolocarbazole multikinase inhibitor, reverts tumorigenic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-κB. Molecular Cancer Therapeutics 2016;15(5):806–18. DOI: 10.1158/1535-7163.MCT-15-0791.

10. Kiseleva M.P., Pokrovsky V.S., Borisova L.M. et al. N-glycosidesindolo[2,3,-a]pyrrolo[3,4,-c]carbazole derivatives chemical structure influence on antitumor activity. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2019;18(2):32–39 (In Russ.).

11. Sánchez C., Méndez C., Salas J.A. Engineering biosynthetic pathways to generate antitumor indolocarbazole derivatives. J Ind Microbiol Biotechnol 2006;33(7):560–8. DOI: 10.1007/s10295-006-0092-5.

12. Zhang G., Shen J., Cheng H. et al. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars. J Med Chem 2005;48(7):2600–11. DOI: 10.1021/jm0493764.

13. Moreau P., Holbeck S., Prudhomme M., Sausville E.A. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. Anti-Cancer Drugs 2005;16(2):145–50. DOI: 10.1097/00001813-200502000-00005.

14. Golubeva I.S., Eremina V.A., Moiseeva N.I. et al. A derivative of the class of T-glycosides of indolo[2,3-a]pyrrolo [3,4-c]carbazole-5,7-dione-N-{12-(βD-xylopyranosole)-5,7-dioxo)indolo[2,3-a]- pyrrolo[3,4-c]carbazol-6-yl}pyridin-2- carboxamide. RU patent 2667906, 25.09.2018 (In Russ.).

15. Kaluzhny D.N., Tatarskiy Jr. V.V., Dezhenkova L.G. et al. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA. Chem Med Chem 2009;4(10):1641–8. DOI: 10.1002/cmdc.200900227.

16. Lantsova A.V., Sanarova K.V., Oborotova N.A. et al. Development of technology for injectable dosage form based on the national substance from the class of indolocarbazoles. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2014;13(3):25–32 (In Russ.).

17. Treschalina E.M., Zhukova O.S., Gerasimova G.K. et al. Methodical recommendations for the preclinical study of the antitumor activity of drugs. In: Guidelines for conducting preclinical studies of drugs. Part one. Moscow: Grif i K., 2012. Pp. 642–57 (In Russ.).

18. Treschalina E.M., Andronova N.V., Garin A.M. Preclinical study of antitumor drugs. In: Rational pharmacotherapy. Moscow: Litterra, 2015. Рp. 75–82 (In Russ.).

19. Experimental evaluation of antitumor drugs in the USSR and the USA. Ed. Z.P. Sofina, A.B. Syrkin (USSR), A. Goldin, A. Klein (USA). Moscow: Medicine, 1980. 296 p. (In Russ.).

20. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy: Principles and Practice. 3rd ed., Philadelphia: Lippincott-Raven, 2001. Рp. 678–90.